Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donna S. Neuberg, D.Sc.

Co-Author

This page shows the publications co-authored by Donna Neuberg and Jeffrey Zwicker.
Connection Strength

2.513
  1. Heparin induced thrombocytopenia antibodies in Covid-19. Am J Hematol. 2020 Jul 13.
    View in: PubMed
    Score: 0.233
  2. Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism. Res Pract Thromb Haemost. 2020 Jul; 4(5):860-865.
    View in: PubMed
    Score: 0.232
  3. Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv. 2020 05 26; 4(10):2254-2260.
    View in: PubMed
    Score: 0.231
  4. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019 02 21; 4(4).
    View in: PubMed
    Score: 0.211
  5. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2019 01; 17(1):72-76.
    View in: PubMed
    Score: 0.208
  6. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017 06 22; 129(25):3379-3385.
    View in: PubMed
    Score: 0.186
  7. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight. 2017 01 12; 2(1):e89373.
    View in: PubMed
    Score: 0.183
  8. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015 Jul 23; 126(4):494-9.
    View in: PubMed
    Score: 0.163
  9. Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. J Clin Oncol. 2014 Jun 10; 32(17):1792-6.
    View in: PubMed
    Score: 0.152
  10. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb; 160(4):530-7.
    View in: PubMed
    Score: 0.138
  11. Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. J Thromb Haemost. 2012 Jul; 10(7):1449-51.
    View in: PubMed
    Score: 0.133
  12. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res. 2012 Apr; 129 Suppl 1:S85-7.
    View in: PubMed
    Score: 0.131
  13. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009 Nov 15; 15(22):6830-40.
    View in: PubMed
    Score: 0.111
  14. Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. Blood Coagul Fibrinolysis. 2008 Jan; 19(1):55-9.
    View in: PubMed
    Score: 0.098
  15. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 11; 98:106459.
    View in: PubMed
    Score: 0.059
  16. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.